Krsnaa DiagnosticsNSE:KRSNAA +0.13%71 Net Margin % is 21.66% as of Mar. 2026, which is 84% above its 10-year median of 11.79. GuruFocus rates NSE:KRSNAA with a GF Score™ of 71/100 and a GF Value™ of ₹898.08 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Krsnaa Diagnostics ranks better than 83.74% on this metric.
The historical rank and industry rank for Krsnaa Diagnostics's Net Margin % or its related term are showing as below:
NSE:KRSNAA'
s Net Margin % Range Over the Past 10 Years
Min: -43.32 Med: 11.79 Max: 46.65
Current: 13.13
NSE:KRSNAA's Net Margin % is ranked better than 83.74% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.43
vs NSE:KRSNAA: 13.13
Krsnaa Diagnostics (NSE:KRSNAA) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Krsnaa Diagnostics Net Margin % Related Terms
Krsnaa Diagnostics Net Margin % Historical Data
* Premium members only.
The historical data trend for Krsnaa Diagnostics's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:KRSNAA vs TMO, DHR, IDXX: Net Margin % Comparison
For the Diagnostics & Research subindustry, Krsnaa Diagnostics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Krsnaa Diagnostics Net Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Krsnaa Diagnostics's Net Margin % distribution charts can be found below:
* The bar in red indicates where Krsnaa Diagnostics's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Krsnaa Diagnostics (NSE:KRSNAA) has a Net Margin % of 21.66% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Krsnaa Diagnostics and its competitors. This is 84% above median its historical median of 11.79. According to the industry distribution chart, Krsnaa Diagnostics ranks #33 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 16.3%.
Is Krsnaa Diagnostics' Net Margin % too high?
Krsnaa Diagnostics' current Net Margin % of 21.66% is 84% above median its 10-year median of 11.79. Based on the distribution chart, Krsnaa Diagnostics ranks #33 out of 203 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Krsnaa Diagnostics has a GF Score™ of 71/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Krsnaa Diagnostics' Net Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Krsnaa Diagnostics ranks #33 out of 203 companies for Net Margin %. This places Krsnaa Diagnostics in the top 16% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Diagnostics & Research company?
A good Net Margin % depends on the Medical Diagnostics & Research industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Krsnaa Diagnostics and its competitors. Krsnaa Diagnostics's current Net Margin % is 21.66%, which is 84% above median its own 10-year median of 11.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krsnaa Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Krsnaa Diagnostics (NSE:KRSNAA) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹898.08, compared to a current price of ₹538.25 — trading 40.1% below its estimated fair value. The current Net Margin % is 21.66%, which is 84% above median its 10-year median of 11.79. Krsnaa Diagnostics' overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Krsnaa Diagnostics (NSE:KRSNAA), the current Net Margin % is 21.66% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Krsnaa Diagnostics (NSE:KRSNAA) Overvalued in 2026?
Based on GuruFocus' analysis, Krsnaa Diagnostics stock appears to be undervalued.
The current stock price of ₹538.25 is trading 40.1% below its estimated GF Value™ of ₹898.08.
GuruFocus considers Krsnaa Diagnostics to be Significantly Undervalued.
Key valuation signals for NSE:KRSNAA:
Net Margin %: 21.66% (84% above median its 10-year median of 11.79)
GF Value™: ₹898.08 vs. price of ₹538.25 (40.1% below fair value)
No single metric tells the full story. See the NSE:KRSNAA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Krsnaa Diagnostics Ltd is a diagnostic services provider, both in Radiology and Pathology. It offers a wide range of diagnostic services such as imaging/radiology services, routine clinical laboratory tests, pathology, and tele-radiology services to private and public hospitals, medical colleges, and community health centres. The company's operations predominantly relate to providing Radiology and Pathology services for X Ray, CT Scan, MRI, Mammography, tele-reporting services, and all types of Blood and Urine investigations.
71GF Score
Get the complete analysis for NSE:KRSNAA
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:KRSNAA has been successfully added to your 
